NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation (NASDAQ: ON ), Entegris, Inc. (NASDAQ: ENTG ), Universal Corporation (NYSE: UVV ), MarineMax, Inc. (NYSE: HZO ), Epizyme, Inc. (NASDAQ: EPZM ), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
ON DOWNLOAD: http://Fundamental-Markets.com/register/?so=ON ENTG DOWNLOAD: http://Fundamental-Markets.com/register/?so=ENTG UVV DOWNLOAD: http://Fundamental-Markets.com/register/?so=UVV HZO DOWNLOAD: http://Fundamental-Markets.com/register/?so=HZO EPZM DOWNLOAD: http://Fundamental-Markets.com/register/?so=EPZM MACK DOWNLOAD: http://Fundamental-Markets.com/register/?so=MACK
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine ON Semiconductor Corporation (NASDAQ: ON ), Entegris, Inc. (NASDAQ: ENTG ), Universal Corporation (NYSE: UVV ), MarineMax, Inc. (NYSE: HZO ), Epizyme, Inc. (NASDAQ: EPZM ), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 8th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ON SEMICONDUCTOR CORPORATION (ON) REPORT OVERVIEW
ON Semiconductor's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, ON Semiconductor reported revenue of $1,541.70MM vs $1,390.90MM (up 10.84%) and analysts estimated basic earnings per share $0.39 vs $0.26 (up 50.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ON Semiconductor reported revenue of $5,543.10MM vs $3,906.90MM (up 41.88%) and analysts estimated basic earnings per share $1.92 vs $0.44 (up 336.36%). Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.40. The estimated EPS forecast for the next fiscal year is $2.08 and is expected to report on February 7th, 2020.
To read the full ON Semiconductor Corporation (ON) report, download it here: http://Fundamental-Markets.com/register/?so=ON
-----------------------------------------
ENTEGRIS, INC. (ENTG) REPORT OVERVIEW
Entegris' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Entegris reported revenue of $398.60MM vs $345.59MM (up 15.34%) and analysts estimated basic earnings per share $0.34 vs $0.29 (up 17.24%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Entegris reported revenue of $1,342.53MM vs $1,175.27MM (up 14.23%) and analysts estimated basic earnings per share $0.60 vs $0.69 (down 13.04%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $2.31 and is expected to report on February 4th, 2020.
To read the full Entegris, Inc. (ENTG) report, download it here: http://Fundamental-Markets.com/register/?so=ENTG
-----------------------------------------
UNIVERSAL CORPORATION (UVV) REPORT OVERVIEW
Universal's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Universal reported revenue of $636.11MM vs $653.58MM (down 2.67%) and analysts estimated basic earnings per share $1.12 vs $1.80 (down 37.78%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Universal reported revenue of $2,033.95MM vs $2,071.22MM (down 1.80%) and analysts estimated basic earnings per share $4.18 vs $0.89 (up 369.66%). Analysts expect earnings to be released on May 22nd, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Universal Corporation (UVV) report, download it here: http://Fundamental-Markets.com/register/?so=UVV
-----------------------------------------
MARINEMAX, INC. (HZO) REPORT OVERVIEW
MarineMax's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, MarineMax reported revenue of $241.94MM vs $236.92MM (up 2.12%) and basic earnings per share $0.22 vs $0.19 (up 15.79%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, MarineMax reported revenue of $1,177.37MM vs $1,052.32MM (up 11.88%) and analysts estimated basic earnings per share $1.77 vs $0.98 (up 80.61%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.25. The estimated EPS forecast for the next fiscal year is $2.13 and is expected to report on October 29th, 2019.
To read the full MarineMax, Inc. (HZO) report, download it here: http://Fundamental-Markets.com/register/?so=HZO
-----------------------------------------
EPIZYME, INC. (EPZM) REPORT OVERVIEW
Epizyme's Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Epizyme reported revenue of $10.00MM vs $8.01MM (up 24.89%) and analysts estimated basic earnings per share -$2.18 vs -$1.93. Analysts expect earnings to be released on March 12th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.52. The estimated EPS forecast for the next fiscal year is -$2.23 and is expected to report on March 12th, 2019.
To read the full Epizyme, Inc. (EPZM) report, download it here: http://Fundamental-Markets.com/register/?so=EPZM
-----------------------------------------
MERRIMACK PHARMACEUTICALS, INC. (MACK) REPORT OVERVIEW
Merrimack Pharmaceuticals' Recent Financial Performance
Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.89. The estimated EPS forecast for the next fiscal year is -$3.59 and is expected to report on March 11th, 2019.
To read the full Merrimack Pharmaceuticals, Inc. (MACK) report, download it here: http://Fundamental-Markets.com/register/?so=MACK
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com
© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
